Myriad offers a scalable approach to hereditary cancer testing and reproductive precision screening, providing personalized education and actionable genetic insights to inform treatment decisions for women in your care. We aim to improve quality of care and patient satisfaction by reducing the cost of healthcare while promoting preventative care and population health initiatives.
Myriad supports your population health initiatives with affordable, best-in-class hereditary cancer testing and reproductive precision screening supported by scalable patient education , cost transparency , staff training, and integration guidance.
We can help your organization prioritize preventative care and patient outcomes through actionable, genetic insights that inform treatment decisions for the women in your care throughout their health journey, from pre-pregnancy to post-menopause. Offer on-demand, personalized education to help patients see the value in testing right away.
Myriad works with systems like yours to help develop program workflows, integrate ordering within your EMR, provide ongoing staff training, enable patient screening, streamline patient payment details, and educate patients before and after the test. Women at risk of hereditary cancer and those looking for information about their future or current pregnancy deserve a genetic testing approach that doesn’t leave anyone out, regardless of their ancestry or BMI.
But to deliver, your health system needs a genetic testing provider that puts patients first with a scalable approach that is simple, streamlined, and integrates into your clinical workflow and EMR with user-friendly ordering and results. Together, we can identify how to implement a program that works in your health system — and supports your commitment to the best care.
By submitting your personal information, you agree to be contacted with newsletters, marketing or promotional materials, and other information that may be of interest to you. You may opt-out of receiving communications from us by following the unsubscribe link or the instructions provided in the communication we send.
For further information on our privacy practices and commitment to protecting your privacy, please visit ourA multi-state health system’s hereditary cancer risk assessment program began with one clinician recognizing an opportunity to improve patients’ lives and the quality of care at her clinic. It became the framework for identifying and treating the women in their care who are at high-risk for hereditary cancer. Read how they did it.
“Affecting communities at the population health level can make lasting changes for generations to come. Moving away from a one-size-fits-all approach to cancer risk assessment and management improves quality of care and patient satisfaction. ”Health systems need to reduce the cost of healthcare without sacrificing quality. A programmatic approach to women’s hereditary cancer risk assessment can help.
Health systems need to reduce the cost of healthcare without sacrificing quality. A programmatic approach to women’s hereditary cancer risk assessment can help. Case StudyAccording to a review of public data, 36% of Americans have at least one first-degree relative with cancer. Yet, a 2022 Myriad survey revealed that 30% of women don’t know whether their family has a history of cancer.
The Clinical Impact of Myriad Women’s Health on Hereditary Cancer Risk Assessment and Genetic Testing Genetic tests aren’t all the same. Learn why you need to consider accuracy, scientific rigor, and service offerings when deciding on which tests to use. Genetic testing isn’t just about the results. Risk assessment, education, and counseling are also required.
Learn how to identify testing labs that align with your value-based care goals. Ancestry and BMI can sometimes make it difficult to get accurate genetic test results for pregnant women. Learn what to look for in prenatal testing. Waldman, R, DeFrancesco, M, Feltz, J, et al.
FACS. Online Screening and Virtual Patient Education for Hereditary Cancer Risk Assessment and Testing. Obstetrics & Gynecology. 145:p 177-185, February 2025 Blumen H, Fitch K, Polkus V. Comparison of treatment costs for breast cancer, by tumor stage and type of service. Am Health Drug Benefits. 2016;9:23–32. https://pmc.ncbi.nlm.nih.gov/articles/ PMC4822976/
Genetic Testing Hereditary Cancer Risk Assessment Patient Education Ancestry BMI Pregnancies Cost Transparency Programs Population Health Health Systems Quality Of Care
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Photos show West Point military competition testing future soldiersWEST POINT, N.Y. (AP) — Amid the Iran war, tensions with European allies in NATO and the Russia-Ukraine war, the United States Military Academy held its 59th Sandhurst Military Skills Competition.
Read more »
Medicare scam targets seniors with fake genetic testing offersSeniors across the country are being targeted by a growing Medicare scam that starts with a simple phone call.
Read more »
Dem governor in the hot seat after testing limits of authority with major move against ICEFox News Channel offers its audiences in-depth news reporting, along with opinion and analysis encompassing the principles of free people, free markets and diversity of thought, as an alternative to the left-of-center offerings of the news marketplace.
Read more »
Netflix is testing its own voice search feature and it sounds less frustratingTech Product Reviews, How To, Best Ofs, deals and Advice
Read more »